Page last updated: 2024-12-08

rosoxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rosoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by an ethyl group at position 1 and by a pyridin-4-yl group at position 7. An antibacterial drug, active against Neisseria gonorrhoeae, it has been used for treating urinary tract infections and certain sexually transmitted diseases. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID287180
CHEMBL ID291157
CHEBI ID131715
SCHEMBL ID135645
MeSH IDM0075544

Synonyms (68)

Synonym
roxadyl
OPREA1_128096
win-35123
eradacin
eracine
pd 107522
1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid
1-ethyl-4-oxo-7-(4-pyridyl)quinoline-3-carboxylic acid
winuron
win 35,213
3-quinolinecarboxylic acid,4-dihydro-4-oxo-7-(4-pyridinyl)-
40034-42-2
rosoxacin
eradacil
nsc146617
win 35213
1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid
acrosoxacin
nsc-146617
DB00817
roxadyl (tn)
D02305
rosoxacin (usan/inn)
rosoxacinum [inn-latin]
3-quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-
rosoxacino [inn-spanish]
rosoxacine [inn-french]
einecs 254-758-4
nsc 146617
win-35213
CHEMBL291157
winoxacin
eradicin
win-35,213
rosoxacinum
rosoxacina
rosoxacine
1-ethyl-4-oxo-7-(pyridin-4-yl)-1,4-dihydroquinoline-3-carboxylic acid
CHEBI:131715
1-ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
rosoxacino
unii-3y1ot3j4nw
rosoxacin [usan:inn:ban]
3y1ot3j4nw ,
SCHEMBL135645
rosoxacin [inn]
rosoxacin [mart.]
rosoxacin [usan]
rosoxacin [who-dd]
rosoxacin [mi]
XBPZXDSZHPDXQU-UHFFFAOYSA-N
DTXSID90193091
AKOS027460752
AC1324
1-ethyl-4-oxo-7-(4-pyridinyl)-1,4-dihydro-3-quinolinecarboxylic acid, aldrichcpr
1-ethyl-4-oxo-7-(4-pyridyl)-1,4-dihydroquinoline-3-carboxylic acid
FT-0722899
SY038205
mfcd00057294
HY-A0208
CS-0017556
Q754690
CS-12131
EN300-18536122
gtpl12474
acrosoxacin hemisulfate
1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)-3-quinolinecarboxylic acid hemisulfate
rosoxacin hemisulfate

Research Excerpts

Actions

ExcerptReferenceRelevance
"Rosoxacin exhibited a lower activity with MIC90s 2 to 16 fold higher against Enterobacteriaceae and P."( In vitro antibacterial activity of three new quinolone derivatives: rosoxacin, norfloxacin, pefloxacin.
Husson, MO; Izard, D; Leclerc, H, 1984
)
1.22

Pharmacokinetics

ExcerptReferenceRelevance
" The plasma data for each subject were described by an open one-compartment body model with first-order absorption, and the pharmacokinetic parameters were determined."( Pharmacokinetics of rosoxacin in human volunteers.
Edelson, J; Park, GB; Saneski, J; Weng, T, 1982
)
0.59

Dosage Studied

ExcerptRelevanceReference
" Ciprofloxacin is effective in single dosage against urogenital gonococcal infections, and probably also against rectal and pharyngeal infections."( Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis.
Oriel, JD, 1986
)
0.27
" We concluded that rosoxacin at a dosage of 300 mg administered orally was fairly effective in the treatment of gonococcal urethritis in men caused by both PPNG and non-PPNG strains."( Rosoxacin in the treatment of uncomplicated gonorrhoea in men.
Ariyarit, C; Chitwarakorn, A; Panikabutra, K; Saensanoh, C, 1984
)
2.04
" In mice dosed orally with 97, sustained plasma drug levels were evident that may account for the high efficacy observed."( 3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents.
Bacon, ER; Bailey, TR; Brundage, RP; Carabateas, PM; Castaldi, MJ; Dorff, PH; Perni, RB; Wentland, MP; Woods, MG; Young, DC, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
quinolinemonocarboxylic acidAny aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID69782Antibacterial activity against Escherichia coli (H560)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID209776Minimum Inhibitory concentration measured against Streptococcus pyogenes ATCC 63011995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID115921Antibacterial activity against Pseudomonas aeruginosa 12 microbial strains in mice was determined expressed as MIC1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID113423Antibacterial activity against Escherichia coli P-5101 microbial strains in mice was determined expressed as ED50 (mg/kg)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID163281Minimum Inhibitory concentration measured against Pseudomonas aeruginosa ATCC 278531995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID64061Compound was tested in vitro for antibacterial activity against the microbial strain Escherichia coli NIHJ JC-2.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID41277Minimum Inhibitory concentration measured against Bacteroides fragilis ATCC 252851995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID164385Antibacterial activity against Pseudomonas aeruginosa (UI-18)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID69784Antibacterial activity against Escherichia coli (vogel)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID210022Antibacterial activity against Streptococcus pneumoniae (SV-1)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID115922Antibacterial activity against Staphylococcus aureus 50774 microbial strains in mice was determined expressed as MIC1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID78707MIC at which cleaved DNA (linear) is observed at an intensity relative to oxolinic acid at 10 ug/mL by using Gyrase Induced DNA-Cleavage assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID113422Antibacterial activity (oral efficacy) against systemic infections due to Staphylococcus aureus 50774 microbial strains in mice was determined1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID69668Minimum Inhibitory concentration measured against Escherichia coli ATCC 1-259221995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID200251Compound was tested in vitro for antibacterial activity against the microbial strain Staphylococcus aureus 209P JC-1.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID115918Antibacterial activity against Escherichia coli P-5101 microbial strains in mice was determined expressed as MIC1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID206021Minimum Inhibitory concentration measured against Staphylococcus aureus ATCC 292131995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID78688Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID207175Antibacterial activity against Staphylococcus aureus (H228)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID209257Minimum Inhibitory concentration measured against Streptococcus faecalis ATCC 292121995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and antibacterial activity of some novel 1-substituted 1,4-dihydro-4-oxo-7-pyridinyl-3-quinolinecarboxylic acids. Potent antistaphylococcal agents.
AID95885Antibacterial activity against Klebsiella pneumonia (MGH-2)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay.
AID218205In vitro minimum inhibitory concentration against herpes simplex virus-2 (HSV-2) by plaque-reduction assay in vero cells1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents.
AID218208In vitro maximum tolerated level against herpes simplex virus-2 (HSV-2) by plaque-reduction assay in vero cells1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents.
AID113424Antibacterial activity against Pseudomonas aeruginosa 12 microbial strains in mice was determined expressed as ED50 (mg/kg)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
AID150898Compound was tested in vitro for antibacterial activity against the microbial strain Pseudomonas aeruginosa 12.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Pyridonecarboxylic acids as antibacterial agents. 9. Synthesis and antibacterial activity of 1-substituted 6-fluoro-1,4-dihydro-4-oxo-7-(4-pyridyl)-1,8-naphthyridine-3- carboxylic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-199069 (89.61)18.7374
1990's4 (5.19)18.2507
2000's1 (1.30)29.6817
2010's2 (2.60)24.3611
2020's1 (1.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.97 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index32.40 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (16.87%)5.53%
Reviews1 (1.20%)6.00%
Case Studies2 (2.41%)4.05%
Observational0 (0.00%)0.25%
Other66 (79.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]